{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-331113","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2025-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.674504+00:00","generated_at":"2026-05-16T12:17:15.299408+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"confidence":"high","headline":"Sensei Bio sets CEO salary at $425K, SVP at $400K; retention bonuses tied to Feb 2026","bullets":["Annual base salaries: Christopher Gerry $425,000, Josiah Craver $400,000, effective Nov 14, 2025.","Each eligible for target annual bonus equal to 40% of base salary beginning FY 2026.","First retention bonus equals full 2025 target bonus if employed through Feb 13, 2026 or terminated without cause.","Second retention bonus is prorated 2026 target bonus if terminated without cause before 2026 bonus payment; 2x multiplier if not change-in-control.","Severance benefits require execution of separation agreement and release of claims."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-331113","json":"https://secwatch.observer/filing/0001193125-25-331113.json","markdown":"https://secwatch.observer/filing/0001193125-25-331113.md","text":"https://secwatch.observer/filing/0001193125-25-331113.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525331113/0001193125-25-331113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525331113/d68669d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:17:15.299408+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}